FR2837101B1 - Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques - Google Patents

Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques

Info

Publication number
FR2837101B1
FR2837101B1 FR0203070A FR0203070A FR2837101B1 FR 2837101 B1 FR2837101 B1 FR 2837101B1 FR 0203070 A FR0203070 A FR 0203070A FR 0203070 A FR0203070 A FR 0203070A FR 2837101 B1 FR2837101 B1 FR 2837101B1
Authority
FR
France
Prior art keywords
adamantyl
methoxyphenyl
treatment
naphthoic acid
dermatological disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0203070A
Other languages
English (en)
Other versions
FR2837101A1 (fr
Inventor
Michael Graeber
Janusz Czernielewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0203070A priority Critical patent/FR2837101B1/fr
Priority to ARP030100823A priority patent/AR038924A1/es
Priority to KR1020047014228A priority patent/KR101007161B1/ko
Priority to CA002478237A priority patent/CA2478237C/fr
Priority to EP03712109A priority patent/EP1485080B1/fr
Priority to PT03712109T priority patent/PT1485080E/pt
Priority to BRPI0307550A priority patent/BRPI0307550B8/pt
Priority to PL372317A priority patent/PL216763B1/pl
Priority to DE60327745T priority patent/DE60327745D1/de
Priority to PT05003144T priority patent/PT1532974E/pt
Priority to RU2004130308/15A priority patent/RU2332208C2/ru
Priority to AT03712109T priority patent/ATE432072T1/de
Priority to SI200331650T priority patent/SI1485080T1/sl
Priority to SI200331464T priority patent/SI1532974T1/sl
Priority to DK03712109T priority patent/DK1485080T3/da
Priority to AU2003216898A priority patent/AU2003216898B2/en
Priority to AT05003144T priority patent/ATE417610T1/de
Priority to DE60325379T priority patent/DE60325379D1/de
Priority to PCT/EP2003/003246 priority patent/WO2003075908A1/fr
Priority to JP2003574183A priority patent/JP2005526063A/ja
Priority to ES05003144T priority patent/ES2319778T3/es
Priority to HK05105000.2A priority patent/HK1073996B/en
Priority to EP05003144A priority patent/EP1532974B1/fr
Priority to DK05003144T priority patent/DK1532974T3/da
Priority to CN038058391A priority patent/CN1642538B/zh
Priority to ES03712109T priority patent/ES2327508T3/es
Priority to MXPA04008684A priority patent/MXPA04008684A/es
Publication of FR2837101A1 publication Critical patent/FR2837101A1/fr
Application granted granted Critical
Publication of FR2837101B1 publication Critical patent/FR2837101B1/fr
Priority to ZA200405853A priority patent/ZA200405853B/xx
Priority to US10/937,612 priority patent/US7579377B2/en
Priority to US11/494,693 priority patent/US7737181B2/en
Priority to US12/103,182 priority patent/US7838558B2/en
Priority to RU2008118056/15A priority patent/RU2377981C1/ru
Priority to AU2008203279A priority patent/AU2008203279B2/en
Priority to CY20091100266T priority patent/CY1108868T1/el
Priority to US12/437,008 priority patent/US7834060B2/en
Priority to CY20091100860T priority patent/CY1109307T1/el
Priority to US12/772,861 priority patent/US7868044B2/en
Priority to US12/902,931 priority patent/US20110027367A1/en
Priority to US12/902,972 priority patent/US8703820B2/en
Priority to JP2010254916A priority patent/JP5722598B2/ja
Priority to US12/957,882 priority patent/US8921423B2/en
Priority to US13/024,681 priority patent/US8729127B2/en
Priority to US13/475,827 priority patent/US8653140B2/en
Priority to US14/222,185 priority patent/US9381179B2/en
Priority to US14/263,758 priority patent/US9387187B2/en
Priority to US14/524,602 priority patent/US9622994B2/en
Priority to US15/175,188 priority patent/US9872842B2/en
Priority to US15/184,262 priority patent/US9901556B2/en
Priority to US15/456,933 priority patent/US20170181991A1/en
Priority to US15/846,663 priority patent/US20180104203A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
FR0203070A 2002-03-12 2002-03-12 Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques Expired - Fee Related FR2837101B1 (fr)

Priority Applications (50)

Application Number Priority Date Filing Date Title
FR0203070A FR2837101B1 (fr) 2002-03-12 2002-03-12 Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques
ARP030100823A AR038924A1 (es) 2002-03-12 2003-03-11 Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos
KR1020047014228A KR101007161B1 (ko) 2002-03-12 2003-03-12 피부병 치료를 위한 아다팔렌의 용도
CA002478237A CA2478237C (fr) 2002-03-12 2003-03-12 Emploi d'adapalene pour le traitement de troubles dermatologiques
EP03712109A EP1485080B1 (fr) 2002-03-12 2003-03-12 Emploi d'adapalene pour le traitement de troubles dermatologiques
PT03712109T PT1485080E (pt) 2002-03-12 2003-03-12 Utilização de adapaleno para o tratamento de desordens dermatológicas
BRPI0307550A BRPI0307550B8 (pt) 2002-03-12 2003-03-12 composição farmacêutica em gel tópica, de adapaleno 0,3%
PL372317A PL216763B1 (pl) 2002-03-12 2003-03-12 Kompozycja farmaceutyczna i zastosowanie kwasu 6-[3-(1-adamantylo)-4-metoksyfenylo]-2-naftalenokarboksylowego do wytwarzania kompozycji farmaceutycznej
DE60327745T DE60327745D1 (de) 2002-03-12 2003-03-12 Verwendung von adapalen zur behandlung dermatologischer erkrankungen
PT05003144T PT1532974E (pt) 2002-03-12 2003-03-12 Composição compreendendo ácido 6-[3-(1-adamantil)-4- metoxifenil]-2-naftóico para o tratamento de desordens dermatológicas
RU2004130308/15A RU2332208C2 (ru) 2002-03-12 2003-03-12 Применение 6-[3-(1-адамантил)-4-метоксифенил]-2-нафтойной кислоты для лечения дерматологических расстройств
AT03712109T ATE432072T1 (de) 2002-03-12 2003-03-12 Verwendung von adapalen zur behandlung dermatologischer erkrankungen
SI200331650T SI1485080T1 (sl) 2002-03-12 2003-03-12 Uporaba adapalena za zdravljenje dermatoloških motenj
SI200331464T SI1532974T1 (sl) 2002-03-12 2003-03-12 Zmes, ki vsebuje 6-(3-(1-adamantil)-4-metoksifenil)-2-naftensko kislino, za zdravljenje dermatoloških motenj
DK03712109T DK1485080T3 (da) 2002-03-12 2003-03-12 Anvendelse af adapalen til behandling af dermatologiske sygdomme
AU2003216898A AU2003216898B2 (en) 2002-03-12 2003-03-12 Use of adapalene for the treatment of dermatological disorders
AT05003144T ATE417610T1 (de) 2002-03-12 2003-03-12 Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
DE60325379T DE60325379D1 (de) 2002-03-12 2003-03-12 Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
PCT/EP2003/003246 WO2003075908A1 (fr) 2002-03-12 2003-03-12 Emploi d'adapalene pour le traitement de troubles dermatologiques
JP2003574183A JP2005526063A (ja) 2002-03-12 2003-03-12 皮膚疾患を治療するためのアダパレンの使用
ES05003144T ES2319778T3 (es) 2002-03-12 2003-03-12 Composiciones que comprenden acido 6-(3-(1-adamantil)-4-metoxifenil)-2-naftanoici para tratamiento de enfermedades dermatologicas.
HK05105000.2A HK1073996B (en) 2002-03-12 2003-03-12 Use of adapalene for the treatment of dermatological disorders
EP05003144A EP1532974B1 (fr) 2002-03-12 2003-03-12 Composition comprenant de l'acide 6-[3-(1-adamantyl)-4-méthoxyphényl]-2-naphthanoique pour le traitement de troubles dermatologiques
DK05003144T DK1532974T3 (da) 2002-03-12 2003-03-12 Sammensætning, der omfatter 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthsyre, til behandling af dermatologiske lidelser
CN038058391A CN1642538B (zh) 2002-03-12 2003-03-12 阿达帕林治疗皮肤病的用途
ES03712109T ES2327508T3 (es) 2002-03-12 2003-03-12 Empleo de adapaleno para el tratamiento de trastornos dermatologicos.
MXPA04008684A MXPA04008684A (es) 2002-03-12 2003-03-12 Uso de adapaleno para tratamiento de trastornos dermatologicos.
ZA200405853A ZA200405853B (en) 2002-03-12 2004-07-22 Use of adapalene for the treatment of dermatological disorders
US10/937,612 US7579377B2 (en) 2002-03-12 2004-09-10 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US11/494,693 US7737181B2 (en) 2002-03-12 2006-07-28 Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US12/103,182 US7838558B2 (en) 2002-03-12 2008-04-15 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
RU2008118056/15A RU2377981C1 (ru) 2002-03-12 2008-05-05 Применение 6-[3-(1-адамантил)-4-метоксифенил]-2-нафтойной кислоты для лечения дерматологических расстройств
AU2008203279A AU2008203279B2 (en) 2002-03-12 2008-07-23 Use of adapalene for the treatment of dermatological disorders
CY20091100266T CY1108868T1 (el) 2002-03-12 2009-03-10 Συνθεση περιλαμβανουσα 6-[3-( 1 -αδαμαντυλο)-4-μεθοξυφαινυλo]-2-ναφθοϊκο οξυ για την θεραπεια δερματολογικων διαταραχων
US12/437,008 US7834060B2 (en) 2002-03-12 2009-05-07 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
CY20091100860T CY1109307T1 (el) 2002-03-12 2009-08-12 Χρηση αδαπαλενιου για τη θεραπεια δερματολογικων διαταραχων
US12/772,861 US7868044B2 (en) 2002-03-12 2010-05-03 Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
US12/902,931 US20110027367A1 (en) 2002-03-12 2010-10-12 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US12/902,972 US8703820B2 (en) 2002-03-12 2010-10-12 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
JP2010254916A JP5722598B2 (ja) 2002-03-12 2010-11-15 皮膚疾患を治療するためのアダパレンを含む薬剤組成物
US12/957,882 US8921423B2 (en) 2002-03-12 2010-12-01 Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
US13/024,681 US8729127B2 (en) 2002-03-12 2011-02-10 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US13/475,827 US8653140B2 (en) 2002-03-12 2012-05-18 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US14/222,185 US9381179B2 (en) 2002-03-12 2014-03-21 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US14/263,758 US9387187B2 (en) 2002-03-12 2014-04-28 Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US14/524,602 US9622994B2 (en) 2002-03-12 2014-10-27 Method for the treatment of acne using pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
US15/175,188 US9872842B2 (en) 2002-03-12 2016-06-07 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US15/184,262 US9901556B2 (en) 2002-03-12 2016-06-16 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
US15/456,933 US20170181991A1 (en) 2002-03-12 2017-03-13 Method for the treatment of acne using pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
US15/846,663 US20180104203A1 (en) 2002-03-12 2017-12-19 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0203070A FR2837101B1 (fr) 2002-03-12 2002-03-12 Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques

Publications (2)

Publication Number Publication Date
FR2837101A1 FR2837101A1 (fr) 2003-09-19
FR2837101B1 true FR2837101B1 (fr) 2004-07-02

Family

ID=27772059

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0203070A Expired - Fee Related FR2837101B1 (fr) 2002-03-12 2002-03-12 Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques

Country Status (4)

Country Link
KR (1) KR101007161B1 (fr)
AR (1) AR038924A1 (fr)
FR (1) FR2837101B1 (fr)
ZA (1) ZA200405853B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100798853B1 (ko) * 2005-02-15 2008-01-28 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
FR2901701B1 (fr) 2006-05-31 2010-10-29 Galderma Res & Dev Compostions comprenant au moins un derive de l'acide naphtoique et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations
FR2903603B1 (fr) 2006-07-13 2009-03-20 Galderma Res & Dev S N C Snc Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne
EP2097076A1 (fr) * 2006-11-20 2009-09-09 Galderma Research & Development, S.N.C. Utilisation d'adapalène pour moduler l'expression de l'il-1ra.
EP2097075A1 (fr) * 2006-11-20 2009-09-09 Galderma Research & Development, S.N.C. Utilisation d'adapalène pour moduler l'expression de cd1d ou il-10.
US20130131177A1 (en) 2010-02-09 2013-05-23 Galderma Research & Development Use of a dermatological composition comprising a combination of adapalene and benzoyl peroxide which is intended for the treatment of acne in non-caucasian population with decrease of post-inflammatory hyperpigmentation
CA2796412A1 (fr) 2010-04-29 2011-11-03 Galderma Research & Development Methode de traitement des cicatrices par l'adapalene a 0,3%
WO2013175011A1 (fr) 2012-05-25 2013-11-28 Galderma Research & Development Traitement d'acne vulgaris modéré chez un préadolescent
WO2016079262A1 (fr) * 2014-11-20 2016-05-26 Galderma Sa Compositions comprenant un compose de la famille des avermectines et un compose agoniste d'au moins un des recepteurs de l'acide retinoique pour le traitement de l'acne
KR102486502B1 (ko) * 2015-09-15 2023-01-09 주식회사 엘지생활건강 여드름 치료제 전달을 위한 용해성 미세바늘 패치

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (fr) * 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques
FR2730930B1 (fr) * 1995-02-27 1997-04-04 Oreal Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique

Also Published As

Publication number Publication date
KR20040111394A (ko) 2004-12-31
AR038924A1 (es) 2005-02-02
KR101007161B1 (ko) 2011-01-12
FR2837101A1 (fr) 2003-09-19
ZA200405853B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1986624A4 (fr) Procédé d'utilisation de l'acide abscisique pour le traitement et la prévention de maladies et de troubles
FR15C0030I2 (fr) Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies
FR2837101B1 (fr) Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques
EP1532974A3 (fr) Gel aqueux comprenant de l'acide 6-[3-(1-adamantyl)-4-méthoxyphényl]-2-naphthanoique pour le traitement de troubles dermatologiques
EP1644039A4 (fr) Compositions et procedes pour le traitement des troubles lies a la coagulation
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP1461323A4 (fr) Composes destines au traitement de troubles metaboliques
EP1536804A4 (fr) Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae
FR13C0029I1 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP2056848A4 (fr) Utilisation d'extraits pour le traitement de troubles viraux
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
FR2902324B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
EP1427323A4 (fr) Utilisation de signalisation s-nitrosothiol pour le traitement de troubles du controle respiratoire
EP3813816A4 (fr) Utilisation de l'acide (s)-3-amino-4-(difluorométhylényl)cyclopent-1-ène-1-carboxylique et de composés apparentés, de l'acide (1s,3s)-3-amino-4-(difluorométhylidène)cyclopentane-1-carboxylique et de la vigabatrine dans le traitement de troubles du développement
DK1248608T3 (da) Diacerein til anvendelse i behandling af psoriasis
DZ2316A1 (fr) Micro sphères pharmaceutiques d'acide valproique pour administration orale.
FR2918993B1 (fr) Utilisation de diesters d'acide carboxylique pour le traitement de textiles et formulation.
EP1581243A4 (fr) Lactoferrine orale pour le traitement des sepsies
EP1484406A4 (fr) Procede de fabrication d'acide n-acetylneuraminique
FR2890562B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2830449B1 (fr) Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
FR2840809B1 (fr) Utilisation d'une fraction hydrophile de fruit de hippophae rhamnoides pour la prevention et le traitement du derme
EP1551397A4 (fr) Composes de guanidine utilises en anesthesie et dans le traitement des troubles du systeme nerveux

Legal Events

Date Code Title Description
CA Change of address
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

ST Notification of lapse

Effective date: 20201110